Sarlósejtes vérszegénység: vizsgálatok itt: Kanada

In Kanada 14 Also abroad 204

14 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.

2. fázisTaking people
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
Where
Montreal, Toronto
Életkor
16 év to 50 év
People
65
Run by
Biossil Inc.
See details and how to joinNCT07282210
4. fázisCsak meghívásos
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Where
Hamilton, Toronto
Életkor
18 év and over
People
55 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00
2. fázisTaking people
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Where
Toronto
Életkor
6 hónap to 18 év
People
95 worldwide
Run by
Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00
3. fázisTaking people
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Where
Montreal, Toronto, Vancouver
Életkor
2 év and over
People
480 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00
3. fázisTaking people
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Where
Calgary, Edmonton, London, Montreal, Scarborough Village, Toronto, Vancouver
Életkor
12 év and over
People
510 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00
2/3. fázisTaking people
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
Where
Montreal
Életkor
6 hónap to 18 év
People
29
Run by
Yves Pastore
See details and how to joinNCT06761560
1/2. fázisTaking people
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Where
Vancouver
Életkor
18 év and over
People
224 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06481306 · EU 2023-510283-12-00
3. fázisCsak meghívásos
A Long-term Follow-up Study in Participants Who Received CTX001
Where
Toronto, Vancouver
Életkor
2 év to 64 év
People
160 worldwide
Run by
Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00
No phaseTaking people
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
Where
Calgary, Montreal, Toronto, Vancouver, Winnipeg
Életkor
3 év to 20 év
People
480 worldwide
Run by
University of Rochester
See details and how to joinNCT06941389
2. fázisTaking people
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Where
Calgary
Életkor
1 év to 19 év
People
12
Run by
University of Calgary
See details and how to joinNCT03214354
2. fázisTaking people
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Where
Calgary, Toronto
Életkor
2 év to 25 év
People
100 worldwide
Run by
Robert Nickel
See details and how to joinNCT03587272
1/2. fázisCsak meghívásos
The BENeFiTS Trial in Beta Thalassemia Intermedia
Where
Toronto
Életkor
18 év and over
People
36 worldwide
Run by
Phoenicia BioScience
See details and how to joinNCT04432623
No phaseCsak meghívásos
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Where
Ottawa, Toronto
Életkor
12 év to 50 év
People
54 worldwide
Run by
Editas Medicine, Inc.
See details and how to joinNCT06363760
No phaseCsak meghívásos
SCRIPT: Sickle Cell Risk in Pregnancy Tool
Where
Montreal, Vancouver
Életkor
16 év to 60 év
People
1000 worldwide
Run by
Mount Sinai Hospital, Canada
See details and how to joinNCT06529042